---
document_datetime: 2025-11-23 12:42:21
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/dificlir.html
document_name: dificlir.html
version: success
processing_time: 0.1233329
conversion_datetime: 2025-12-24 02:57:14.293442
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Dificlir

[RSS](/en/individual-human-medicine.xml/66376)

##### Authorised

This medicine is authorised for use in the European Union

fidaxomicin

Medicine

Human

Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Dificlir](#news-on)
- [More information on Dificlir](#related-medicines)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Dificlir is a medicine used to treat children and adults with infections of the gut caused by bacteria called *Clostridioides difficile* .

Dificlir contains the active substance fidaxomicin.

Expand section

Collapse section

## How is Dificlir used?

Dificlir is available as tablets (200 mg) or granules for oral suspension (40 mg/ml) and can only be obtained with a prescription.

In adults and children weighing at least 12.5 kg, the recommended dose is 200 mg twice a day (every 12 hours) for 10 days. For children weighing less than 12.5 kg, the dose depends on the bodyweight. For more information about using Dificlir, see the package leaflet or contact your doctor or pharmacist.

## How does Dificlir work?

*C. difficile* are bacteria that are present naturally in the gut and do not cause any problems in healthy people. This is because they are kept under control by other 'good' bacteria which are beneficial to the body and enhance health. However, some antibiotics that are used to treat infections can interfere with the balance and kill the 'good' bacteria in the gut. When this happens, *C. difficile* bacteria can multiply and produce toxins (poisons) which cause illness such as diarrhoea and fever. At this point, a person is said to be infected with *C. difficile* .

The active substance in Dificlir, fidaxomicin, is an antibiotic that belongs to the class of macrocylic antibiotics. When it is swallowed most of the active substance does not get absorbed into the blood stream but acts locally on C. difficile bacteria in the gut. It works by blocking the bacterial enzyme RNA polymerase, which is used to produce the genetic material that the bacteria need to make proteins.

This stops the *C. difficile* bacteria from growing and multiplying, thereby reducing the symptoms of the disease.

## What benefits of Dificlir have been shown in studies?

Dificlir was at least as effective as vancomycin (another antibiotic for *C. difficile* infections) in three main studies in patients with mild to moderately severe *C. difficile* infection. The results of two studies involving a total of 1,147 adults showed that 92% of patients taking Dificlir were cured after 10 days compared with 90% of patients taking vancomycin.

In the third study, which involved 148 patients aged from birth to 18 years, 78% of patients taking Dificlir were cured 2 days after the end of treatment, compared with 71% of patients taking vancomycin.

## What are the risks associated with Dificlir?

The most common side effects with Dificlir (which may affect up to 1 in 10 people) are nausea (feeling sick), vomiting and constipation. For the full list of side effects and restrictions with Dificlir, see the package leaflet.

## What measures are being taken to ensure the safe and effective use of Dificlir?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Dificlir have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Dificlir are continuously monitored. Side effects reported with Dificlir are carefully evaluated and any necessary action taken to protect patients.

## Other information about Dificlir

Dificlir received a marketing authorisation valid throughout the EU on 5 December 2011.

Dificlir : EPAR - Medicine overview

Reference Number: EMA/31758/2020

English (EN) (109.92 KB - PDF)

**First published:** 19/12/2011

**Last updated:** 11/03/2020

[View](/en/documents/overview/dificlir-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-838)

български (BG) (141.03 KB - PDF)

**First published:**

19/12/2011

**Last updated:**

11/03/2020

[View](/bg/documents/overview/dificlir-epar-medicine-overview_bg.pdf)

español (ES) (110.58 KB - PDF)

**First published:**

19/12/2011

**Last updated:**

11/03/2020

[View](/es/documents/overview/dificlir-epar-medicine-overview_es.pdf)

čeština (CS) (131.56 KB - PDF)

**First published:**

19/12/2011

**Last updated:**

11/03/2020

[View](/cs/documents/overview/dificlir-epar-medicine-overview_cs.pdf)

dansk (DA) (110.21 KB - PDF)

**First published:**

19/12/2011

**Last updated:**

11/03/2020

[View](/da/documents/overview/dificlir-epar-medicine-overview_da.pdf)

Deutsch (DE) (112.45 KB - PDF)

**First published:**

19/12/2011

**Last updated:**

11/03/2020

[View](/de/documents/overview/dificlir-epar-medicine-overview_de.pdf)

eesti keel (ET) (107.09 KB - PDF)

**First published:**

19/12/2011

**Last updated:**

11/03/2020

[View](/et/documents/overview/dificlir-epar-medicine-overview_et.pdf)

ελληνικά (EL) (134.22 KB - PDF)

**First published:**

19/12/2011

**Last updated:**

11/03/2020

[View](/el/documents/overview/dificlir-epar-medicine-overview_el.pdf)

français (FR) (111.01 KB - PDF)

**First published:**

19/12/2011

**Last updated:**

11/03/2020

[View](/fr/documents/overview/dificlir-epar-medicine-overview_fr.pdf)

hrvatski (HR) (130.79 KB - PDF)

**First published:**

19/12/2011

**Last updated:**

11/03/2020

[View](/hr/documents/overview/dificlir-epar-medicine-overview_hr.pdf)

italiano (IT) (109.38 KB - PDF)

**First published:**

19/12/2011

**Last updated:**

11/03/2020

[View](/it/documents/overview/dificlir-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (146.05 KB - PDF)

**First published:**

19/12/2011

**Last updated:**

11/03/2020

[View](/lv/documents/overview/dificlir-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (131.72 KB - PDF)

**First published:**

19/12/2011

**Last updated:**

11/03/2020

[View](/lt/documents/overview/dificlir-epar-medicine-overview_lt.pdf)

magyar (HU) (130.08 KB - PDF)

**First published:**

19/12/2011

**Last updated:**

11/03/2020

[View](/hu/documents/overview/dificlir-epar-medicine-overview_hu.pdf)

Malti (MT) (141.17 KB - PDF)

**First published:**

19/12/2011

**Last updated:**

11/03/2020

[View](/mt/documents/overview/dificlir-epar-medicine-overview_mt.pdf)

Nederlands (NL) (110.14 KB - PDF)

**First published:**

19/12/2011

**Last updated:**

11/03/2020

[View](/nl/documents/overview/dificlir-epar-medicine-overview_nl.pdf)

polski (PL) (131.78 KB - PDF)

**First published:**

19/12/2011

**Last updated:**

11/03/2020

[View](/pl/documents/overview/dificlir-epar-medicine-overview_pl.pdf)

português (PT) (111.52 KB - PDF)

**First published:**

19/12/2011

**Last updated:**

11/03/2020

[View](/pt/documents/overview/dificlir-epar-medicine-overview_pt.pdf)

română (RO) (137.4 KB - PDF)

**First published:**

19/12/2011

**Last updated:**

11/03/2020

[View](/ro/documents/overview/dificlir-epar-medicine-overview_ro.pdf)

slovenčina (SK) (131.45 KB - PDF)

**First published:**

19/12/2011

**Last updated:**

11/03/2020

[View](/sk/documents/overview/dificlir-epar-medicine-overview_sk.pdf)

slovenščina (SL) (129.3 KB - PDF)

**First published:**

19/12/2011

**Last updated:**

11/03/2020

[View](/sl/documents/overview/dificlir-epar-medicine-overview_sl.pdf)

Suomi (FI) (108.1 KB - PDF)

**First published:**

19/12/2011

**Last updated:**

11/03/2020

[View](/fi/documents/overview/dificlir-epar-medicine-overview_fi.pdf)

svenska (SV) (109.29 KB - PDF)

**First published:**

19/12/2011

**Last updated:**

11/03/2020

[View](/sv/documents/overview/dificlir-epar-medicine-overview_sv.pdf)

Dificlir : EPAR - Risk-management-plan summary

English (EN) (219.06 KB - PDF)

**First published:** 21/01/2019

**Last updated:** 11/03/2020

[View](/en/documents/rmp-summary/dificlir-epar-risk-management-plan-summary_en.pdf)

## Product information

Dificlir : EPAR - Product Information

English (EN) (532.54 KB - PDF)

**First published:** 19/12/2011

**Last updated:** 30/09/2024

[View](/en/documents/product-information/dificlir-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-188)

български (BG) (661.45 KB - PDF)

**First published:**

19/12/2011

**Last updated:**

30/09/2024

[View](/bg/documents/product-information/dificlir-epar-product-information_bg.pdf)

español (ES) (575.13 KB - PDF)

**First published:**

19/12/2011

**Last updated:**

30/09/2024

[View](/es/documents/product-information/dificlir-epar-product-information_es.pdf)

čeština (CS) (653.67 KB - PDF)

**First published:**

19/12/2011

**Last updated:**

30/09/2024

[View](/cs/documents/product-information/dificlir-epar-product-information_cs.pdf)

dansk (DA) (528.28 KB - PDF)

**First published:**

19/12/2011

**Last updated:**

30/09/2024

[View](/da/documents/product-information/dificlir-epar-product-information_da.pdf)

Deutsch (DE) (571.39 KB - PDF)

**First published:**

19/12/2011

**Last updated:**

30/09/2024

[View](/de/documents/product-information/dificlir-epar-product-information_de.pdf)

eesti keel (ET) (530.73 KB - PDF)

**First published:**

19/12/2011

**Last updated:**

30/09/2024

[View](/et/documents/product-information/dificlir-epar-product-information_et.pdf)

ελληνικά (EL) (769.91 KB - PDF)

**First published:**

19/12/2011

**Last updated:**

30/09/2024

[View](/el/documents/product-information/dificlir-epar-product-information_el.pdf)

français (FR) (592.97 KB - PDF)

**First published:**

19/12/2011

**Last updated:**

30/09/2024

[View](/fr/documents/product-information/dificlir-epar-product-information_fr.pdf)

hrvatski (HR) (615.99 KB - PDF)

**First published:**

19/12/2011

**Last updated:**

30/09/2024

[View](/hr/documents/product-information/dificlir-epar-product-information_hr.pdf)

íslenska (IS) (536.44 KB - PDF)

**First published:**

19/12/2011

**Last updated:**

30/09/2024

[View](/is/documents/product-information/dificlir-epar-product-information_is.pdf)

italiano (IT) (591.02 KB - PDF)

**First published:**

19/12/2011

**Last updated:**

30/09/2024

[View](/it/documents/product-information/dificlir-epar-product-information_it.pdf)

latviešu valoda (LV) (663.63 KB - PDF)

**First published:**

19/12/2011

**Last updated:**

30/09/2024

[View](/lv/documents/product-information/dificlir-epar-product-information_lv.pdf)

lietuvių kalba (LT) (601.49 KB - PDF)

**First published:**

19/12/2011

**Last updated:**

30/09/2024

[View](/lt/documents/product-information/dificlir-epar-product-information_lt.pdf)

magyar (HU) (658.89 KB - PDF)

**First published:**

19/12/2011

**Last updated:**

30/09/2024

[View](/hu/documents/product-information/dificlir-epar-product-information_hu.pdf)

Malti (MT) (693.07 KB - PDF)

**First published:**

19/12/2011

**Last updated:**

30/09/2024

[View](/mt/documents/product-information/dificlir-epar-product-information_mt.pdf)

Nederlands (NL) (576.41 KB - PDF)

**First published:**

19/12/2011

**Last updated:**

30/09/2024

[View](/nl/documents/product-information/dificlir-epar-product-information_nl.pdf)

norsk (NO) (544.87 KB - PDF)

**First published:**

19/12/2011

**Last updated:**

30/09/2024

[View](/no/documents/product-information/dificlir-epar-product-information_no.pdf)

polski (PL) (675.62 KB - PDF)

**First published:**

19/12/2011

**Last updated:**

30/09/2024

[View](/pl/documents/product-information/dificlir-epar-product-information_pl.pdf)

português (PT) (535.28 KB - PDF)

**First published:**

19/12/2011

**Last updated:**

30/09/2024

[View](/pt/documents/product-information/dificlir-epar-product-information_pt.pdf)

română (RO) (605.06 KB - PDF)

**First published:**

19/12/2011

**Last updated:**

30/09/2024

[View](/ro/documents/product-information/dificlir-epar-product-information_ro.pdf)

slovenčina (SK) (671.53 KB - PDF)

**First published:**

19/12/2011

**Last updated:**

30/09/2024

[View](/sk/documents/product-information/dificlir-epar-product-information_sk.pdf)

slovenščina (SL) (608.07 KB - PDF)

**First published:**

19/12/2011

**Last updated:**

30/09/2024

[View](/sl/documents/product-information/dificlir-epar-product-information_sl.pdf)

Suomi (FI) (522.6 KB - PDF)

**First published:**

19/12/2011

**Last updated:**

30/09/2024

[View](/fi/documents/product-information/dificlir-epar-product-information_fi.pdf)

svenska (SV) (525.95 KB - PDF)

**First published:**

19/12/2011

**Last updated:**

30/09/2024

[View](/sv/documents/product-information/dificlir-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** IB/0052/G 01/12/2023

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Dificlir : EPAR - All Authorised presentations

English (EN) (23.49 KB - PDF)

**First published:** 19/12/2011

**Last updated:** 11/03/2020

[View](/en/documents/all-authorised-presentations/dificlir-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-835)

български (BG) (40.36 KB - PDF)

**First published:**

19/12/2011

**Last updated:**

11/03/2020

[View](/bg/documents/all-authorised-presentations/dificlir-epar-all-authorised-presentations_bg.pdf)

español (ES) (23.7 KB - PDF)

**First published:**

19/12/2011

**Last updated:**

11/03/2020

[View](/es/documents/all-authorised-presentations/dificlir-epar-all-authorised-presentations_es.pdf)

čeština (CS) (37.86 KB - PDF)

**First published:**

19/12/2011

**Last updated:**

11/03/2020

[View](/cs/documents/all-authorised-presentations/dificlir-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (23.79 KB - PDF)

**First published:**

19/12/2011

**Last updated:**

11/03/2020

[View](/da/documents/all-authorised-presentations/dificlir-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (15.39 KB - PDF)

**First published:**

19/12/2011

**Last updated:**

11/03/2020

[View](/de/documents/all-authorised-presentations/dificlir-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (17.79 KB - PDF)

**First published:**

19/12/2011

**Last updated:**

11/03/2020

[View](/et/documents/all-authorised-presentations/dificlir-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (37.45 KB - PDF)

**First published:**

19/12/2011

**Last updated:**

11/03/2020

[View](/el/documents/all-authorised-presentations/dificlir-epar-all-authorised-presentations_el.pdf)

français (FR) (23.93 KB - PDF)

**First published:**

19/12/2011

**Last updated:**

11/03/2020

[View](/fr/documents/all-authorised-presentations/dificlir-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (42.15 KB - PDF)

**First published:**

19/12/2011

**Last updated:**

11/03/2020

[View](/hr/documents/all-authorised-presentations/dificlir-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (24.21 KB - PDF)

**First published:**

19/12/2011

**Last updated:**

11/03/2020

[View](/is/documents/all-authorised-presentations/dificlir-epar-all-authorised-presentations_is.pdf)

italiano (IT) (13.48 KB - PDF)

**First published:**

19/12/2011

**Last updated:**

11/03/2020

[View](/it/documents/all-authorised-presentations/dificlir-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (39.39 KB - PDF)

**First published:**

19/12/2011

**Last updated:**

11/03/2020

[View](/lv/documents/all-authorised-presentations/dificlir-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (41.38 KB - PDF)

**First published:**

19/12/2011

**Last updated:**

11/03/2020

[View](/lt/documents/all-authorised-presentations/dificlir-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (41.25 KB - PDF)

**First published:**

19/12/2011

**Last updated:**

11/03/2020

[View](/hu/documents/all-authorised-presentations/dificlir-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (36.5 KB - PDF)

**First published:**

19/12/2011

**Last updated:**

11/03/2020

[View](/mt/documents/all-authorised-presentations/dificlir-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (23.8 KB - PDF)

**First published:**

19/12/2011

**Last updated:**

11/03/2020

[View](/nl/documents/all-authorised-presentations/dificlir-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (23.8 KB - PDF)

**First published:**

19/12/2011

**Last updated:**

11/03/2020

[View](/no/documents/all-authorised-presentations/dificlir-epar-all-authorised-presentations_no.pdf)

polski (PL) (41.44 KB - PDF)

**First published:**

19/12/2011

**Last updated:**

11/03/2020

[View](/pl/documents/all-authorised-presentations/dificlir-epar-all-authorised-presentations_pl.pdf)

português (PT) (23.71 KB - PDF)

**First published:**

19/12/2011

**Last updated:**

11/03/2020

[View](/pt/documents/all-authorised-presentations/dificlir-epar-all-authorised-presentations_pt.pdf)

română (RO) (31.35 KB - PDF)

**First published:**

19/12/2011

**Last updated:**

11/03/2020

[View](/ro/documents/all-authorised-presentations/dificlir-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (39.39 KB - PDF)

**First published:**

19/12/2011

**Last updated:**

11/03/2020

[View](/sk/documents/all-authorised-presentations/dificlir-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (40.05 KB - PDF)

**First published:**

19/12/2011

**Last updated:**

11/03/2020

[View](/sl/documents/all-authorised-presentations/dificlir-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (23.97 KB - PDF)

**First published:**

19/12/2011

**Last updated:**

11/03/2020

[View](/fi/documents/all-authorised-presentations/dificlir-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (24.17 KB - PDF)

**First published:**

19/12/2011

**Last updated:**

11/03/2020

[View](/sv/documents/all-authorised-presentations/dificlir-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Dificlir Active substance fidaxomicin International non-proprietary name (INN) or common name fidaxomicin Therapeutic area (MeSH) Clostridium Infections Anatomical therapeutic chemical (ATC) code A07AA12

### Pharmacotherapeutic group

Antidiarrheals, intestinal antiinflammatory / antiinfective agents

### Therapeutic indication

Dificlir film-coated tablets is indicated for the treatment of Clostridioides difficile infections (CDI) also known as C. difficile-associated diarrhoea (CDAD) in adult and paediatric patients with a body weight of at least 12.5 kg.

Consideration should be given to official guidelines on the appropriate use of antibacterial agents.

Dificlir granules for oral suspension is indicated for the treatment of Clostridioides  difficile infections (CDI) also known as C. difficile-associated diarrhoea (CDAD) in adults and paediatric patients from birth to &lt; 18 years of age.

Consideration should be given to official guidelines on the appropriate use of antibacterial agents.

## Authorisation details

EMA product number EMEA/H/C/002087 Marketing authorisation holder

Tillotts Pharma GmbH

Warmbacher Strasse 80

Opinion adopted 22/09/2011 Marketing authorisation issued 05/12/2011 Revision 18

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Dificlir : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (232.11 KB - PDF)

**First published:** 23/03/2012

**Last updated:** 30/09/2024

[View](/en/documents/procedural-steps-after/dificlir-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Dificlir-H-C-002087-X-0034-G : EPAR - Assessment Report - Extension

Adopted

Reference Number: EMA/4852/2020

English (EN) (1.48 MB - PDF)

**First published:** 11/03/2020

[View](/en/documents/variation-report/dificlir-h-c-002087-x-0034-g-epar-assessment-report-extension_en.pdf)

CHMP post-authorisation summary of positive opinion for Dificlir (X-34)

Adopted

Reference Number: EMA/CHMP/515208/2019

English (EN) (157.31 KB - PDF)

**First published:** 13/12/2019

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-dificlir-x-34_en.pdf)

Dificlir-H-C-2087-P46-0022 : EPAR - Assessment Report

Adopted

Reference Number: EMA/773298/2014

English (EN) (580.32 KB - PDF)

**First published:** 16/02/2015

**Last updated:** 16/02/2015

[View](/en/documents/variation-report/dificlir-h-c-2087-p46-0022-epar-assessment-report_en.pdf)

Dificlir-EMEA-H-C-2087-PSUV-0015: EPAR - Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation

Reference Number: EMA/223574/2014

English (EN) (60.89 KB - PDF)

**First published:** 25/04/2014

**Last updated:** 25/04/2014

[View](/en/documents/scientific-conclusion/dificlir-emea-h-c-2087-psuv-0015-epar-scientific-conclusions-and-grounds-recommending-variation-terms-marketing-authorisation_en.pdf)

## Initial marketing authorisation documents

Dificlir : EPAR - Public assessment report

Adopted

Reference Number: EMA/857570/2011

English (EN) (966.4 KB - PDF)

**First published:** 19/12/2011

**Last updated:** 19/12/2011

[View](/en/documents/assessment-report/dificlir-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Dificlir

Adopted

Reference Number: EMA/CHMP/724015/2011

English (EN) (46.33 KB - PDF)

**First published:** 23/09/2011

**Last updated:** 23/09/2011

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-dificlir_en.pdf)

#### News on Dificlir

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 9-12 December 2019](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-9-12-december-2019) 13/12/2019

#### More information on Dificlir

- [EMEA-000636-PIP01-09-M07 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-000636-pip01-09-m07)

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 30/09/2024

## Share this page

[Back to top](#main-content)